Low sexual desire is the most common sexual issue reported by women. By some estimates, upwards of 50 percent of women experience its effects. What types of women are most likely to suffer from low ...
AOL: Drug for low sexual desire gets first-ever OK for postmenopausal women
The Food and Drug Administration has approved a historic first in women’s sexual health. Prescription Addyi is now approved to treat low sexual desire in postmenopausal women under 65. The pill was ...
UC San Francisco: First Treatment Guidelines for Low Sexual Desire in Women
For the first time, sexual medicine experts have created treatment guidelines and recommendations for women who experience low sexual desire or Hypoactive Sexual Desire Disorder (HSDD), a common yet ...
WebMD: Addyi: FDA Approves New Treatment for Low Sexual Desire in Postmenopausal Women
What Is Addyi, and Why Does It Matter? Addyi (flibanserin) is a nonhormonal prescription pill that is now approved by the FDA to treat low sexual desire in women younger than 65, including those who ...
Addyi: FDA Approves New Treatment for Low Sexual Desire in Postmenopausal Women
For the first time, postmenopausal women with low sexual desire have an FDA-approved pill designed specifically for them. On Monday, the U.S. Food and Drug Administration approved Addyi (flibanserin) ...
WRAL: FDA approves new drug for women with low sexual desire disorder
The US Food and Drug Administration approved a drug to return sexual desire to some women with low libido, the agency said Friday. The US Food and Drug Administration approved a drug to return sexual ...
On , a new drug, Addyi (ADD-ee, flibanserin), becomes available to treat the 10 percent of women whose low libido, or “female hypoactive sexual desire disorder,” causes significant ...